Latest news

Adalvo’s DCP for Tacrolimus 0.03% and 0.1% Ointment is making significant progress, with closure planned for Q3 2025. Engineered for effective dermal delivery, Tacrolimus Ointment represents a highly specialized R&D achievement,...

Adalvo joins the global community in celebrating World Intellectual Property Day, recognising the vital role of IP in advancing pharmaceutical development. At Adalvo, our strong IP strategy is key to delivering...

Adalvo will submit the DCP for Fidaxomicin 200mg tablets in June 2025, highlighting our commitment to expanding access to high-value antibiotic treatments across global markets, including the U.S.  Based on the...

Adalvo, in collaboration with its strategic partner CNX Therapeutics, has launched Nitrofurantoin Modified Release Tablets in the Netherlands, marking the first generic entry in these markets. Developed in-house, this milestone comes...

Adalvo announces the completion of its global dossier for Dolutegravir, a high-value antiretroviral therapy widely recognized for its pivotal role in HIV treatment.   Dolutegravir, a blockbuster anti-HIV product, is a...

Adalvo continues to expand its specialty generics portfolio with the development of Voclosporin Soft Gel Capsules, a calcineurin inhibitor (CNI) indicated for the treatment of active lupus nephritis (LN) in...

Adalvo, in collaboration with its regional partner, has successfully launched Solifenacin/Tamsulosin in various LATAM markets, marking the first generic entry of this therapy in the region. More launches across the region...

Adalvo is on track to complete the global dossier for Ceftazidime + Avibactam by year-end. Developing this complex antibiotic combination required overcoming significant challenges, including securing limited API sources and...

Eurolab, an exclusive marketing partner of Adalvo in South Africa, has successfully defended its right to provide affordable cancer treatment by revoking the Enzalutamide compound patent, originally set to expire...

Adalvo is actively advancing Tafamidis 61mg Soft Gel Capsules to meet the increasing demand in the Transthyretin-Related Amyloidosis (ATTR) market, with a DCP submission planned for July 2025.  As the only...

Adalvo continues to strengthen its peptide & biosimilar portfolio with the addition of Pancreatin Delayed-Release Capsules, a blockbuster treatment addressing a critical need in Exocrine Pancreatic Insufficiency (EPI).  Pancreatin is the...

Adalvo, in partnership with one of the biggest Latvian medicine manufacturers Olpha, announces the first-to-market launch of Nitrofurantoin ER in the Baltic region and will expand availability to additional European markets in the...

Adalvo strengthens its specialty generics portfolio with the dossier readiness of Tofacitinib XR (11mg).  Backed by a ready-to-register EU CTD dossier, the extended-release (XR) formulation expands Adalvo’s offering and ensures broader treatment...

Adalvo, in collaboration with CNX Therapeutics, has launched Pregabalin Extended-Release (ER) tablets in the United Kingdom, strengthening its position as the first and only company to introduce this value-added formulation...

Adalvo announces the DCP approval for Macitentan 10mg film-coated tablets, marking progress in expanding access to essential treatments for pulmonary arterial hypertension (PAH).  This product is based on the reference brand...

As the world observes World Obesity Day, Adalvo highlights its commitment to addressing the global obesity crisis and its close connection to diabetes. Adalvo’s metabolism and endocrinology portfolio includes 14 INNs,...

On Rare Disease Day, Adalvo highlights its commitment to expanding access to essential treatments for patients with rare diseases. With a targeted portfolio, Adalvo continues to address unmet medical needs by providing...

Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, reinforcing their shared commitment to expanding access to high-quality...

On World Cancer Day, Adalvo highlights its commitment to expanding access to high-quality oncology treatments. With a portfolio of 37 INNs and a total addressable market of $58 billion (according to...